Agreement - January 13, 2015
Stena, Mann Lines Cooperating
Stena Line and Mann Lines have launched a joint RoRo service in the North Sea and Baltic as part of an agreement to support each other’s networks in the region. Stena Line already has an extensive network and is always eager to expand its logistics services and routes. Mann Lines offers a liner RoRo service […]
Agreement - January 13, 2015
MedImmune, Omnis Connect
AstraZeneca’s global biologics research and development arm, MedImmune, has entered into a licensing agreement with Omnis Pharmaceuticals, a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus program, a genetically engineered strain of vesicular […]
Agreement - January 13, 2015
Thermo Scientific Extends Reach
Mohammad Abdullah Al Azzaz Company Limited has implemented Thermo Scientific™ SampleManager LIMS™, an informatics solution for process industries worldwide, to enhance the services offered through the company’s contract testing laboratories. MAAZ is a strategic partner to key contractors in the Middle East focused on serving industry involved with construction material testing, chemical and environmental testing […]
Drug Development Pharma - January 12, 2015
FDA OKs Novo Weight-Loss Drug
Two months after its own deadline, the U.S. Food and Drug Administration (FDA) issued approval for Novo Nordisk’s first weight-loss therapy. Approved was Novo’s Saxenda for use in managing weight in conjunction with diet and exercise. Saxenda is a higher dose of the diabetes treatment liraglutide. The drug is indicated for patients who qualify as […]
Clinical Trials - January 12, 2015
Orphazyme Raises Funds for Trials
Danish biotech company Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk’s venture arm. Orphazyme’s lead candidate, Orph002, is a treatment for Niemann-Pick disease type C (NPC), a rare disorder in which cholesterol […]
Drug Development Pharma - January 12, 2015
2014 Year of Orphan Drugs
The European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing authorization in a single year in 2014. Out of the 82 medicines for human use recommended last year, 17 are meant for the treatment of a rare disease, serving patients who frequently have a few or no treatment options. Among […]
